Advanced

FKBPL: a marker of good prognosis in breast cancer.

Nelson, Laura; McKeen, Hayley D; Marshall, Andrea; Mulrane, Laoighse; Starczynski, Jane; Storr, Sarah J; Lanigan, Fiona; Byrne, Christopher; Arthur, Ken and Hegarty, Shauna, et al. (2015) In Oncotarget 6(14). p.12209-12223
Abstract
FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL's prognostic ability in primary breast cancer tissue, represented on tissue microarrays (TMA) from 3277 women recruited into five independent retrospective studies, using immunohistochemistry (IHC). In a meta-analysis, FKBPL levels were a significant predictor of BCSS; low FKBPL levels indicated poorer breast cancer specific survival (BCSS) (hazard ratio (HR) = 1.30, 95% confidence interval (CI) 1.14-1.49, p < 0.001). The prognostic impact of FKBPL remained significant after adjusting for other known prognostic factors (HR =... (More)
FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL's prognostic ability in primary breast cancer tissue, represented on tissue microarrays (TMA) from 3277 women recruited into five independent retrospective studies, using immunohistochemistry (IHC). In a meta-analysis, FKBPL levels were a significant predictor of BCSS; low FKBPL levels indicated poorer breast cancer specific survival (BCSS) (hazard ratio (HR) = 1.30, 95% confidence interval (CI) 1.14-1.49, p < 0.001). The prognostic impact of FKBPL remained significant after adjusting for other known prognostic factors (HR = 1.25, 95% CI 1.07-1.45, p = 0.004). For the sub-groups of 2365 estrogen receptor (ER) positive patients and 1649 tamoxifen treated patients, FKBPL was significantly associated with BCSS (HR = 1.34, 95% CI 1.13-1.58, p < 0.001, and HR = 1.25, 95% CI 1.04-1.49, p = 0.02, respectively). A univariate analysis revealed that FKBPL was also a significant predictor of relapse free interval (RFI) within the ER positive patient group, but it was only borderline significant within the smaller tamoxifen treated patient group (HR = 1.32 95% CI 1.05-1.65, p = 0.02 and HR = 1.23 95% CI 0.99-1.54, p = 0.06, respectively). The data suggests a role for FKBPL as a prognostic factor for BCSS, with the potential to be routinely evaluated within the clinic. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Oncotarget
volume
6
issue
14
pages
12209 - 12223
publisher
Impact Journals, LLC
external identifiers
  • pmid:25906750
  • wos:000359008200035
  • scopus:84931380443
ISSN
1949-2553
DOI
10.18632/oncotarget.3528
language
English
LU publication?
yes
id
41e2a13a-ee9a-4633-bac9-189ca386b82d (old id 5340822)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25906750?dopt=Abstract
date added to LUP
2015-05-02 13:07:42
date last changed
2017-01-01 06:18:00
@article{41e2a13a-ee9a-4633-bac9-189ca386b82d,
  abstract     = {FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL's prognostic ability in primary breast cancer tissue, represented on tissue microarrays (TMA) from 3277 women recruited into five independent retrospective studies, using immunohistochemistry (IHC). In a meta-analysis, FKBPL levels were a significant predictor of BCSS; low FKBPL levels indicated poorer breast cancer specific survival (BCSS) (hazard ratio (HR) = 1.30, 95% confidence interval (CI) 1.14-1.49, p &lt; 0.001). The prognostic impact of FKBPL remained significant after adjusting for other known prognostic factors (HR = 1.25, 95% CI 1.07-1.45, p = 0.004). For the sub-groups of 2365 estrogen receptor (ER) positive patients and 1649 tamoxifen treated patients, FKBPL was significantly associated with BCSS (HR = 1.34, 95% CI 1.13-1.58, p &lt; 0.001, and HR = 1.25, 95% CI 1.04-1.49, p = 0.02, respectively). A univariate analysis revealed that FKBPL was also a significant predictor of relapse free interval (RFI) within the ER positive patient group, but it was only borderline significant within the smaller tamoxifen treated patient group (HR = 1.32 95% CI 1.05-1.65, p = 0.02 and HR = 1.23 95% CI 0.99-1.54, p = 0.06, respectively). The data suggests a role for FKBPL as a prognostic factor for BCSS, with the potential to be routinely evaluated within the clinic.},
  author       = {Nelson, Laura and McKeen, Hayley D and Marshall, Andrea and Mulrane, Laoighse and Starczynski, Jane and Storr, Sarah J and Lanigan, Fiona and Byrne, Christopher and Arthur, Ken and Hegarty, Shauna and Ali, Ahlam Abdunnabi and Furlong, Fiona and McCarthy, Helen O and Ellis, Ian O and Green, Andrew R and Rakha, Emad and Young, Leonie and Kunkler, Ian and Thomas, Jeremy and Jack, Wilma and Cameron, David and Jirström, Karin and Yakkundi, Anita and McClements, Lana and Martin, Stewart G and Gallagher, William M and Dunn, Janet and Bartlett, John and O'Connor, Darran and Robson, Tracy},
  issn         = {1949-2553},
  language     = {eng},
  number       = {14},
  pages        = {12209--12223},
  publisher    = {Impact Journals, LLC},
  series       = {Oncotarget},
  title        = {FKBPL: a marker of good prognosis in breast cancer.},
  url          = {http://dx.doi.org/10.18632/oncotarget.3528},
  volume       = {6},
  year         = {2015},
}